True precision medicine through single-cell science.
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human's hidden "single-cell" secrets. The performance and clinically-relevant application of Scailyte's platform ScaiVision have been demonstrated in numerous clinical projects that resulted in patent-pending biomarkers. Scailyte has a growing pipeline of clinical projects in immunology, oncology and women's health supported by top clinicians and access to high quality proprietary datasets.
If you want to partner with us and save lives by enabling precision medicine, reach out to contact@scailyte.com
More information about our company, technology & services you can find on our website - https://scailyte.com
Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into diseases and enables ultra-sensitive diagnostics by uncovering human's hidden "single-cell" secrets. The performance and clinically-relevant application of Scailyte's platform ScaiVision have been demonstrated in numerous clinical projects that resulted in patent-pending biomarkers. Scailyte has a growing pipeline of clinical projects in immunology, oncology and women's health supported by top clinicians and access to high quality proprietary datasets.
If you want to partner with us and save lives by enabling precision medicine, reach out to contact@scailyte.com
More information about our company, technology & services you can find on our website - https://scailyte.com
Location: Switzerland, Basel-City, Basel
Employees: 11-50
Total raised: $16.99M
Founded date: 2017
Investors 5
| Date | Name | Website |
| 18.05.2022 | Plug and P... | plugandpla... |
| - | Verve Vent... | verve.vc |
| - | Venture Ki... | venturekic... |
| - | MassChalle... | masschalle... |
| - | VentureLab | venturelab... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 08.01.2024 | Series A | $8M | - |
| 02.10.2022 | Series A | $6.2M | Venture Ki... |
| 19.12.2018 | Seed | $2.79M | - |
Mentions in press and media 46
| Date | Title | Description |
| 12.09.2024 | The Hidden Struggles of X-Linked Hypophosphatemia: A Call for Awareness and Action | X-linked hypophosphatemia (XLH) is a name that may not ring a bell for many. Yet, for those affected, it’s a daily battle. A recent analysis from the XLH Disease Monitoring Program (DMP) sheds light on the harsh realities faced by adults li... |
| 09.09.2024 | More space for healthtech start-ups on the Novartis Campus | Digitalisation is one of the megatrends in the healthcare sector. It not only promises greater efficiency, but also new possibilities in diagnostics and therapeutics. As this field requires expertise that traditional healthcare companies o... |
| 31.05.2024 | Swiss life science startups headed for San Diego | The BIO International Convention 2024, taking place in San Diego from 3 to 6 June, is the largest global biotechnology event with over 20,000 industry leaders from around the world attending. The target group includes representatives from ... |
| 08.01.2024 | Scailyte hits twin peaks: Extends Series A funding to USD 8 Million and transfers endometriosis diagnostic assets to Hera Biotech | Scailyte hits twin peaks: Extends Series A funding to USD 8 Million and transfers endometriosis diagnostic assets to Hera Biotech 08.01.2024 09:56, Rita Longobardi linkedIn facebook twitter instagram youtube --> The strategic agreement a... |
| 08.01.2024 | Scailyte hits twin peaks: Extends Series A funding to USD 8 Million and transfers endometriosis diagnostic assets to Hera Biotech | Last week, Scailyte, a Swiss innovator in single-cell and AI-guided biomarker discovery, agreed with US-based Hera Biotech, marking a crucial moment as Hera acquires Scailyte's endometriosis diagnostic testing assets and associated intellec... |
| 04.01.2024 | Hera Biotech acquires endometriosis diagnostic assets from Scailyte | |
| 05.12.2023 | Scailyte reaches USD 8 million in Series A | |
| 12.05.2023 | Startups welcome seasoned industry leaders to their board | |
| 01.10.2022 | Scailyte Closes CHF6M Series A Funding | Scailyte, a Basel, Switzerland-based med-tech company, raised CHF6M in Series A funding. The round was led by a Swiss family office, Mirabaud bank and existing backers. The company intends to use the funds to accelerate growth, expand opera... |
| 22.09.2022 | Scailyte secures CHF 6 million to advance immuno-oncology |
Show more